Hypertension and its cardiovascular consequences contribute to the leading causes of morbidity and mortality worldwide. 1,2 Approximately, 40-60% of the variation in hypertension is attributed to genetic factors. 3 Numerous genome-wide association studies (GWASs) have identified multiple associations between genetic susceptibility variants with blood pressure (BP). [4] [5] [6] [7] A GWAS in Europeans linking the single nucleotide polymorphism (SNP) rs13082711 located 10 kb of the coding region of SLC4A7 to hypertension. 4 And recently, our large-scale GWAS of BP and hypertension involving a total of 80,962 subjects from Chinese Han ancestry replicated the SLC4A7 locus. 5 However, the reported leading SNP rs13082711 at SLC4A7 associated with BP in Europeans had low minor allele frequency (< 0.05) in the Chinese Han population, and we detected a second variant rs820430 near SLC4A7 as a Chinese-specific variant for hypertension (systolic BP, P = 1.36 × 10 -12 ). The SNP rs13082711 in Europeans and rs820430 identified in our study are not in linkage disequilibrium (r 2 = 0.06 in HapMap JPT + CHB).
Introduction
Hypertension and its cardiovascular consequences contribute to the leading causes of morbidity and mortality worldwide. 1, 2 Approximately, 40-60% of the variation in hypertension is attributed to genetic factors. 3 Numerous genome-wide association studies (GWASs) have identified multiple associations between genetic susceptibility variants with blood pressure (BP). [4] [5] [6] [7] A GWAS in Europeans linking the single nucleotide polymorphism (SNP) rs13082711 located 10 kb of the coding region of SLC4A7 to hypertension. 4 And recently, our large-scale GWAS of BP and hypertension involving a total of 80,962 subjects from Chinese Han ancestry replicated the SLC4A7 locus. 5 However, the reported leading SNP rs13082711 at SLC4A7 associated with BP in Europeans had low minor allele frequency (< 0.05) in the Chinese Han population, and we detected a second variant rs820430 near SLC4A7 as a Chinese-specific variant for hypertension (systolic BP, P = 1.36 × 10 -12 ). The SNP rs13082711 in Europeans and rs820430 identified in our study are not in linkage disequilibrium (r 2 = 0.06 in HapMap JPT + CHB).
The variant rs820430 is located in an intergenic region and the nearest annotated gene, SLC4A7, is ~23 kb from the risk region (Supplementary Figure S1) . The SLC4A7 gene encodes electroneutral Na + , HCO 3 − cotransporter NBCn1, 6 a member of the solute carrier 4 (SLC4) membrane transporter protein involved in kidney acid-base regulation, intracellular pH maintaining and the balance of cation composition. 7, 8 Recent studies showed that NBCn1 knockout mice had a complex BP phenotype and an altered vascular function: NBCn1 knockout mice were moderately hypertensive at rest (∼10 mm Hg) but showed reduced BP response to NO-synthase inhibition and angiotensin II infusion. 9 Consistent with the changes in BP regulation, it was reported that sustained intracellular acidification of endothelial cells induced by knockout of NBCn1 inhibited basal and acetylcholine-stimulated NO synthesis and vasorelaxation. 10 In addition, SLC4A7 was markedly expressed in coronary endothelial cells, and selective pharmacological inhibition as well as knockdown of SLC4A7 aggravated apoptosis in ischemic endothelial cells due to activation of the mitochondrial pathway of apoptosis. 11 However, the variant rs820430 is located in a gene desert, and whether it correlates with nearby SLC4A7 gene expression and the molecular mechanisms underlying these risk associations remained underexplored.
The current study aimed to investigate the function of a regulatory element at the lead variant rs820430 on SLC4A7 transcription and identify the mechanisms for regulating SLC4A7 expression though allele-specific reporter assays, gel mobility shift assays, chromatin immunoprecipitation (ChIP).
MATERIALS AND METHODS

Study subjects
A group of 275 participants from rural district of Shandong Province were enrolled in the China Cardiovascular Health Study project, a population-based investigation of risk factors for cardiovascular diseases in China since 2006. 12 In general, individuals were excluded from the study if they had stage II/III hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg), a history of coronary heart disease, diabetes mellitus, stroke, renal, hepatic disease, or took antihypertensive medications in the past 2 weeks. Standard questionnaire was used by trained interviewers to obtain information on demographic characteristics including age, gender, ethnicity, details of medical history, smoking, and alcohol consumption. The clinical characteristics of subjects were listed in Supplementary Table S1 .
Informed consents were obtained from all subjects and the study protocol conformed to the principles outlined in the Declaration of Helsinki as reflected in a priori approval by the institutional review boards of Fuwai Hospital.
Peripheral blood mononuclear cell isolation
Fasting peripheral blood was collected in the morning after an overnight fast. Peripheral blood mononuclear cells (PBMCs) were isolated from the middle white monolayer by density gradient centrifugation using Lymphocyte Separation Medium (TBD, Tianjin, China) according to the manufacturer' s instructions. Isolated PBMCs were preserved in Trizol reagent (Invitrogen, Carlsbad, CA) at −80 °C.
DNA extraction and genotyping
Blood for genotyping was taken into ethylenediamine tetraacetic acid (EDTA)-containing receptacles; genomic DNA was isolated according to a standard procedure using a DNA extraction kit (Tiangen Biotech, China).
Rs820430 was genotyped using genomic DNA with the fluorogenic 5′-nuclease TaqMan allelic discrimination assay system (Applied Biosystems, CA). The assays were performed under standard conditions on a 7900HT Real-time PCR instrument. Probe and primer sequences can be found in Supplementary Table S2 .
RNA isolation and qRT-PCR analysis
Total RNA from PBMCs was isolated using TRIzol reagent (Invitrogen, Carlsbad) according to the manufacturer's protocol. Genomic DNA contamination was eliminated by TURBO DNA-free (Ambion, Austin), and cDNA was obtained using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Basel, Switzerland). RT-PCR for SLC4A7 was carried out in triplicate using SYBR Green on a Applied Biosystems 7900 HT Fast Real-Time PCR System (Applied Biosystems). Primer sequences were provided in Supplementary Table S2 . The relative mRNA expression levels were normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase and presented as log 2 -transormed expression (∆Ct) ×10 3 .
Cell culture
Human embryonic kidney 293T (HEK293T) cells were grown in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) at 37 °C. Primary human umbilical vein endothelial cells (HUVECs) were isolated from the vascular wall of human umbilical vein by digestion with collagenase type I (Roche, Basel, Switzerland), and cultured in endothelial cell culture medium (ScienCell, CA) with 5% fetal bovine serum, 1% endothelial cell growth supplement, 100 U/ml penicillin, and 100 mg/ml streptomycin sulfate at 37 °C in a humidified incubator with 5% CO 2 .
Plasmid constructs
The genomic sequence of the putative enhancer elements was amplified by PCR from one individual homozygous for the rs820430 C allele and one individual homozygous for the rs820430 T allele. The PCR product was subcloned into the BamHI and XhoI sites of the pGL3-promoter vector (Promega, Madison, WI) to create 2 plasmids: pGL3-promoter-C and pGL3-promoter-T. Both constructs were sequenced to verify that the only ambiguity was the polymorphic site. The primers were listed in Supplementary Table S2. Cell culture, transfection, and luciferase assays HEK293T cells were seeded at a density of 1.0 × 10 5 cells per well in a 24-well plate at 24 h prior to transfection in medium without antibiotics. Transfection was performed with Vigorous transfection reagent (Vigorous Biotechnology, Beijing, China) according to the manufacturer's protocol. One microgram of the luciferase reporter gene was cotransfected with 0.5 µg of pRL-TK (Renilla luciferase; Promega) as an internal control for variations in transfection efficiency. Transfection using pGL3-promoter vector without an insert was used as a negative control. The transfected cells were harvested after 24 h, and the luciferase activity was measured using the dual-luciferase reporter assay system (Promega, Madison, WI) using a luminometer (TD-20; Turner Designs).
Electrophoretic mobility shift assay
Synthetic double-stranded oligonucleotide probes (C: ACCGACCCCTGGCTGCAGCAGCCCC and T: ACCGA CCCCTGGTTGCAGCAGCCCC) corresponding to the genomic sequence with either a C or T allele at the rs820430 site were labelled with biotin (Shanghai Sangon Biological Engineering Technology and Services). Nuclear extracts from HUVECs were prepared with Nuclear-Cytosol Extraction Kit (Applygen Technologies, Beijing, China) according to the manufacturer's protocol. Protein concentrations were determined using a bicinchoninic acid (BCA) assay (Pierce), and the nuclear extracts were stored at −80 °C. Electrophoretic mobility shift assays (EMSAs) were performed by using the LightShiftTM chemiluminescent EMSA kit (Pierce). For each gel-shift reaction (20 µl), a total of 20 fmol of biotin-labelled probes were combined with 15 µg of nuclear extract prepared from HUVECs, 1 µg of poly (dI-dC), and 1 × binding buffer (10 mM Tris-HCl, 50 mM KCl, and 1 mM dithiothreitol; pH 7.5). For competition assays, a 200-fold molar excess of unlabelled C or T probe was preincubated for 5 minutes at room temperature (25 °C) with nuclear extracts before the addition of the labelled probe. The reaction mixture was resolved on a nondenaturing 6% acrylamide gel in 0.5 × Tris/borate/EDTA (TBE (1 × TBE = 45 mM Tris/borate and 1 mM EDTA)) buffer. For supershift assays, HUVECs nuclear extract was preincubated with the antibody against c-Fos (sc-271243, Santa Cruz Biotechnology, Santa Cruz, CA) for 30 minutes at 4 °C. Then the electrophoresized binding reactions were transferred on to nylon membrane, and cross-linking was performed for 5 minutes with a UV cross-linker. The signal of the biotinlabelled DNA bound to the membrane was detected with a LightShiftTM chemiluminescent EMSA kit (Pierce) according to the manufacturer's protocol.
ChIP assays
ChIP assays were performed with the EZ ChIP Kit (Upstate, Lake Placid, NY). Briefly, crosslinked cells were sonicated and immunoprecipitated with antibodies against c-Fos or nonspecific rabbit IgG (Santa Cruz Biotechnology) overnight at 4 °C. The enrichment of immunoprecipitated DNA was assessed by PCR and gel electrophoresis. Allelespecific binding of c-Fos to the rs820430-containing site was verified by DNA sequencing. The primers were listed in Supplementary Table S2 .
Statistical analysis
All statistical analyses were performed with SPSS 17.0 software (SPSS, Chicago, IL). Differences in categorical variables and Hardy-Weinberg equilibrium were tested by a χ 2 test. Comparisons of continuous variables were analyzed by an unpaired t test and analysis of variance, as appropriate. All statistical tests were 2-tailed, and P <0.05 was considered significant. Linkage disequilibrium analysis was performed using Haploview version 4.2. 13 
RESULTS
Association of the T allele of rs820430 with increased expression of SLC4A7 mRNA
The variant rs820430 was located in an intergenic region and the nearest annotated gene was SLC4A7. Thus, to determine whether rs820430 affected SLC4A7 transcription, we compared the mRNA levels of SLC4A7 in PBMCs from 275 individuals among 3 genotypes of rs820430. As shown in Figure 1 , rs820430 was significantly correlated with SLC4A7 expression. The TT homozygotes of rs820430 had a 25.4% increased in the SLC4A7 expression compared with the CC homozygotes (1.18 ± 0.05 vs. 1.47 ± 0.11).
Together, these data showed that the risk T allele of rs820430 associated with increased expression of SLC4A7 mRNA and rs820430 was more likely to be the functional variant for regulating SLC4A7 expression.
Functional prediction of rs820430 in silico
To further explore the mechanisms underlying the regulation of the SLC4A7 gene with respect to rs820430, we mapped regulatory chromatin regions surrounding rs820430 using the ENCylopedia Of DNA Elements (ENCODE) Integrated Regulation data from 7 cell lines. Enrichment for histone modifications H3K4me1 (the enhancer mark) was demonstrated in the region containing rs820430 (Supplementary Figure S2) . Enrichment for H3K27ac (marks active regulatory elements) was also observed to a stronger extent. We also mapped the transcription factor binding sites using ENCODE data, which identified enrichment of c-Fos (activator protein-1; AP-1) component in HUVEC (Figure 2) . Together, the ENCODE data predicted that the regions surrounding rs820430 was likely to be a transcriptional enhancer.
Allele-specific effect of rs820430 on transcriptional activity in vitro
Bioinformatics prediction showed that rs820430 was located in the enriched zone of the enhancer marker H3K4me1, so we further performed biological assays to investigate whether the rs820430 had a direct effect on promoter transcriptional activity.
A genomic fragment carrying either the C or T allele at the site of rs820430 was inserted into the BamHI and XhoI Figure 1 . Association of the T allele of rs820430 with increased expression of SLC4A7 mRNA. Data are shown as means ± SD. and are normalized to GAPDH levels. Expression levels with the TT genotype (n = 25) were significantly higher (P = 0.047) than those with the CT (n = 134) or CC genotype (n = 116). Abbreviation: GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
sites of the firefly luciferase expressing pGL3-promoter vector (Figure 2A ). The activity of these luciferase reporter gene constructs was assessed in transient transfection assays in HEK293T cells.
As expected, data in Figure 2B showed that the luciferase activity of rs820430-promoter constructs was 1-to 2-fold higher than that of the empty vector (P < 0.01). Moreover, to evaluate whether the enhancer activity was allele specific, the acitivty of the T risk allele was compared to that of the C allele in a luciferase reporter assay. Significantly increased reporter activity was observed with the T allele (P = 0.017) ( Figure 2B ). Thus, this result clearly indicated that the hypertension risk region functions as an enhancer, and the rs820430 risk variant drived luciferase activity in an allele specific manner.
c-Fos transcription factor binding to rs820430 in vitro
Functional SNPs usually affect gene expression via specific binding to transcription factors. To elucidate specific nuclear factors that might bind a disease-susceptible allele, we performed EMSAs to determine the nuclear factors that might bind to oligonucleotides corresponding to the genomic sequence of the C or T allele of rs820430, and determined whether the binding of the transcription factors differed for the C and T alleles. Using nuclear extracts from the HUVECs and biotin-labelled probes corresponding to the C or T allele, we observed a band in the T allele but not in the C allele ( Figure 3A These results suggested that the T allele of rs820430 had stronger transcriptional regulatory activity due to specific binding to transcription factor c-Fos.
c-Fos transcription factor binding to rs820430 in intact cells
Transcriptional regulation of gene expression is tightly controlled by the native chromatin architecture in intact Genomic fragment carrying either the C or T allele at the rs420430 site was cloned downstream of the firefly luciferase expressing pGL3-promoter vector into the BamH I and Xho I sites. (B) All constructs were cotransfected into cells with pRL-TK to standardize transfection efficiency. Luciferase activities with pGL-promoter and pRL-TK were determined in triplicate. Fold increase was measured by defining the activity of the empty pGL-promoter vector as 1. Data are shown as the means ± SD from three independent transfection experiments, each performed in triplicate. The luciferase activity of the variant T construct was higher than that of the C construct (P = 0.017). Abbreviation: HEK293T, human embryonic kidney 293T.
cells, therefore, we performed ChIP assays to determine the binding of c-Fos to the site of rs820430 in intact cells. As illustrated in Figure 4A , the ChIP conducted in HUVECs showed that the rs820430-containing region was occupied by the transcription factor c-Fos.
Furthermore, the amplified 131 bp region from ChIP preparation was verified by DNA sequencing, we found that the surrounding sequence of the ChIP enrichment at rs820430 site was TT homozygote ( Figure 4B ).
Taken together, these results demonstrated that rs820430 was within the c-Fos-binding site, and the T allele resulted in a specific binding affinity for c-Fos.
DISCUSSION
Recent GWAS have identified more than 50 independent risk-associated loci for hypertension. 4, 5, 14 However, the molecular mechanisms and relevant pathways underlying these risk associations remain unclear. 15 Herein, using multiple functional analyses, we revealed that the T allele of a new hypertension-associated variant rs820430 significantly increased the transcriptional activity by the detection of SLC4A7 mRNA levels and in vitro luciferase reporter activity. The EMSA and ChIP data suggested that the mechanism of its effect on transcription involved the binding of c-Fos transcription factor to a cis-regulatory enhancer element. This study will help in our understanding of the genetic mechanisms underlying hypertension.
Our previous genetic association studies identified rs820430 as being strongly associated with hypertension in Chinese Han population, with the T allele conferring increased risk. It is a Chinese-specific variant in previous reported regions in European populations, not in linkage disequilibrium (r 2 < 0.2 in HapMap JPT + CHB) with the previously reported SNPs. In addition, this variant also exists in other Asian population, such as Japan population according to HapMap. It is well-known that genetic variants may lead to BP changes by acting on intermediate molecular phenotypes such as coded protein sequence or gene expression, which in turn affect BP. 16 The variant rs820430 is located in an intergenic region and the nearest annotated gene is SLC4A7. SLC4A7 (NBCn1) is an electroneutral sodium bicarbonate cotransporter expressed in the nephron and in vascular smooth muscle, and it has been identified with plausible connections to BP via its function in renal physiology or kidney disease. 17 The present study showed that rs820430 was significantly associated with the expression of SLC4A7 in cohort population. Individuals carrying the risk T allele were found to have greater SLC4A7 expression. These data suggested that rs820430 was likely to be the causal variant for hypertension and the disease-associated T allele linked increased hypertension risk through higher SLC4A7 expression.
Since the risk region is intergenic, the molecular mechanisms underlying disease causation are unknown. The bioinformatics prediction showed that rs820430 was located in the enriched zone of the enhancer marker H3K4me1, and then the luciferase assays demonstrated significantly increasing of reporter activity with the T risk allele compared to the C allele, which was consistent with SLC4A7 expression pattern in PBMCs. Moreover, the rs820430 was located near a c-Fos consensus binding sequence. The EMSA and ChIP data suggested that T allele of rs820430 increased the binding affinity for c-Fos in HUVECs. The oncogene c-Fos is an important member of transcription factor AP-1, together with Jun family members they form the group of AP-1 proteins which, after dimerization, bind to so-called TPA-responsive elements (TGAC/GTCA) in the promoter and enhancer regions of target genes. 18, 19 It has been shown that the AP-1 family of TFs been implicated in growth factor dependent EC and SMC activation following vessel injury. 20 And genes encoding extracellular matrix proteins are often the targets of AP-1 enhancer elements. 19 Further studies are warranted in the future to fully interpret the mechanisms underlying the effects of allele-specific binding with c-Fos on SLC4A7 expression.
In conclusion, this study provided the first evidence that the hypertension risk locus containing rs820430 has in vitro properties of an enhancer. We proposed that this risk locus acts as part of a cis-regulatory enhancer element for the SLC4A7 expression, mediating hypertension risk in part through its differential binding with c-Fos. The findings reported here provided further pathophysiological insight into the common heritable risk of hypertension and potentially lead to new treatment opportunities.
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